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5-Fluorouracil and folinic acid: interesting biochemistry or effective
treatment?
D.J. Kerr
CRC Dept ofMedical Oncology, I Horselethill Road, University ofGlasgow, Glasgow G12 9LX, UK.
While waiting for the introduction of novel, active cytotoxic
agents to the clinic, it behoves us to utilise currently available
anti-neoplastic drugs as best we can. This implies that we
continue to extend knowledge of the drug's clinical and
cellular pharmacology and optimise drug delivery in terms of
dose, route of administration, schedule, combination with
other agents, and circadian ordered timing of administration.
The addition of folinic acid (leucovorin, etc.) to 5-
fluorouracil is one such area where knowledge of the drugs
mechanism has led to proposals for its more effective use in
the clinic.
In essence, 5-Fu is metabolised to 5-dUMP which binds to
and inhibits the enzyme thymidylate synthetase (Figure 1).
The ability of 5-dUMP to inhibit the enzyme is enhanced by
the presence of 5,10-CH2-FH4 which can by synthesised from
FA, and stabilises the formation of a covalent, ternary com-
plex of F-dUMP with thymidylate synthetase (Figure 1).
There are extensive preclinical data, both in vitro and in
vivo (Houghton et al., 1982) suggesting that the combination
of 5-Fu/FA is significantly more efficacious than 5-Fu alone.
In order to provide guidelines for clinical usage, in vitro studies
have been used to define minimum effective concentrations and
durations ofexposure to FA required to maximise the cytotox-
icity of 5-Fu. For example, the lowest concentration of FA
that provided maximum potentiation was 10YM for mouse
sarcoma 180 cells treated with 5-Fu at a concentration of
30 lLM for 3 h. This implies that attempts should be made to
achieve plasma FA concentrations of at least 10JAM and main-
tain these for at least 3 h (Evans et al., 1981). This type of
approach may seem naive, in view of the complex intracellular
metabolism which both drugs must undergo to be 'activated'
and as plasma drug concentrations at best given an indirect
estimate of drug concentration at its molecular target. Never-
theless, this allows us to use the clinical pharmacokinetic
parameters for FA to calculate dose regimens which will
achieve 'ball-park' plasma exposures compared to those con-
sidered active in vitro, and must serve as a more scientific
method of deriving dose schedules than empiricism.
There has been a large number of phase I/II studies of
5-Fu in combination with FA using a range of dose schedules
(for both drugs). Clinical studies have focused mainly on
those tumour types in which 5-Fu has a defined role such as
gastro-intestinal, breast and squamous cell carcinoma of head
and neck.
Machover et al. (1986) performed a phase II trial of 5-Fu/
FA in patients with advanced gastric carcinoma. In
previously treated patients (26 out of 27 available patients),
one CR and 12 PRs were seen (50% objective response rate),
with a median time to disease progression of almost 6
months. Other phase II studies with different dose schedules
show activity, but at lower levels. There are no mature phase
III trials in gastric carcinoma. Phase II studies in advanced
breast cancer, some including patients previously treated with
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Figure 1 Intracellular metabolism of 5-fluorouracil (5-FU) and
folinic acid (FA). FdUrd, fluorodeoxyuridine; FdUMP,
fluorodeoxyuridine monophosphate; dUMP, deoxyuridine
monophosphate; dTMP, thymidylate; 5,10-CH2-FH4, 5,10-
methenyl-tetrahydrofolate; FH2, dihydrofolate; 5-CH3-FH4, 5-
methyltetrahydrofolate; FH4, tetrahydrofolate.
5-Fu containing regimens, generally indicate a range of useful
activity for 5-Fu/FA. Doroshow et al. (1989) have shown
that 5-Fu (bolus 370mg m-2 day-' on days 1 -5) and high
dose folinic acid infusion (500 mg m-2 day-' on days 1-6) is
a useful salvage therapy in patients with refractory metastatic
breast cancer. Sixty patients, who had been previously
treated with 5-Fu containing regimens, were treated with
5-Fu/FA and I CR (duration 8.7 months) and 9 PRs (median
duration 3.2 months) were seen (objective response, 17%,
95% confidence intervals for response, 8-27%).
There is limited evidence suggesting that 5-Fu/FA is active
in locally advanced squamous carcinoma of the head and
neck, but it has already been incorporated into complex split
chemotherapy/radiotherapy regimens for this disease (Wendt
et al., 1989).
The most mature data, in terms of phase III trials, have
been accrued for threatment of patients with advanced col-
orectal carcinoma. An update of current results from seven
randomised trials comparing 5-Fu/FA against single agent
5-Fu was presented recently by O'Connell (1989) at the
NCI-EORTC symposium on new cancer drugs (Amsterdam,
March 1989). Although the dose and treatment schedules
varied, 1,058 patients had been randomised and six of the
seven trials have shown a significantly higher response rate in
the 5-Fu/FA arms. Interestingly two of the trials (O'Connell,
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1989; Erlichman et al., 1986) with similar dose schedules
(bolus 5-Fu, 370-425 mg m-2 day-' on days 1-5; bolus FA,
20 or 200 mg m-2 days-' on days 1-5) demonstrated
significant prolongation of overall survival in the 5-Fu/FA
arm (median survival 1 year vs 7.5 months). Future ran-
domised studies in advanced colo-rectal carcinoma will com-
pare the Roswell Park Memorial schedules (5-Fu bolus of
600 mg m-2 at the mid point of a 2 h infusion of FA,
500 mg m-2 repeated weekly x 6) against the Mayo clinic/
NCCTG schedule (with low dose FA, 20 mg m-2). The
results of the randomised phase III studies provide a strong
scientific rationale for the use of 5-Fu/FA combinations as
surgical adjuvant therapy for patients with colorectal car-
cinoma.
Dose limiting toxicity of the 5-Fu/FA combination
depends on the schedule. It tends to be severe diarrhoea for
weekly administration and mylosuppression, and stomatitis
for the 5 x daily loading course. Certainly in the Mayo
Clinic/NCCTG experience, stomatitis was worse in the com-
bination arm, diarrhoea was mild and evenly distributed and
myelosuppression was more marked with 5-Fu alone. A
quality of life assessment indicated that 5-Fu plus low dose
FA was the preferred treatment.
Is this treatment cost effective? According to our current
hospital pharmacy prices, a 6-week course of 5-Fu/FA ac-
cording to the Roswell Park Memorial Schedule would cost
approximately £540.00 compared to £15.00 for 5-Fu. How-
ever, response rates and survival were similar in the Mayo
Clinic/NCCGT study comparing two different FA schedules
(200 mg m-2 day-' on days 1-5 versus 20 mg m-2 day-' on
days 1-5) and therefore one would conclude from this trial
that 5-Fu/low dose FA was the preferred arm in terms of
cost effectiveness.
Is it possible to refine combination treatment with 5-Fu/
FA further? The notion of having a specific, measurable
biochemical target (the ternary complex with thymidylate
synthetase) for 5-Fu/FA implies an ability to titrate drug
dose schedules almost to an individual level, if there are
correlates between response and tissue biochemical
parameters. Investigators at the NCI and Mayo Clinic are
attempting, prospectively, to estimate the kinetics of forma-
tion of the thymidylate synthetase-F-dUMP complex using a
radioimmuno assay in sequential breast cancer biopsies fol-
lowing treatment with 5-Fu/FA, and relate this to response.
This is a fascinating study and obviously, potentially gives
much more information than measuring plasma drug concen-
trations.
In terms of 5-Fu delivery, there is increasing evidence to
suggest that prolonged, continuous infusions of 5-Fu yield
higher response rates in metastatic colorectal cancer than
conventional bolus (weekly or loading) administration.
Lokich et al. (1989) have recently reported that continuous
infusion of 5-Fu, 300mgm-2day-1 for 10 weeks had a
significantly higher response rate than bolus 5-Fu,
500mgm 2day ' on days 1-5 (30% vs 7%). It may be that
prolonged exposure to 5-Fu leads to stabilisation or a greater
degree of inhibition of thymidylate synthetase than
generating high intracellular drug concentration for brief
periods following bolus administration (5-Fu has a plasma
half-life of approximately 10 min). Obviously, there may be a
potential to combine prolonged infusions of 5-Fu with FA.
This is an interesting field, and we all like to see 'old drugs
learn new tricks', but it is important to remember that the
survival benefits of combined treatment, when conferred, are,
thus far, relatively minor and this treatment combination
should remain the subject of further research rather then
routine clinical application.
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